Pages that link to "Q43863175"

The following pages link to Prognostic factors for response to sildenafil in patients with erectile dysfunction (Q43863175):

Displaying 40 items.

• Role of Schwann cells in the regeneration of penile and peripheral nerves (Q28085669) (← links)
• Research in pharmacotherapy for erectile dysfunction (Q33650796) (← links)
• Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse (Q33854121) (← links)
• A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations. (Q34524277) (← links)
• Intracavernous Delivery of a Designed Angiopoietin-1 Variant Rescues Erectile Function by Enhancing Endothelial Regeneration in the Streptozotocin-Induced Diabetic Mouse (Q34615514) (← links)
• A 4-year update on the safety of sildenafil citrate (Viagra). (Q34987825) (← links)
• Optimizing in vivo gene transfer into mouse corpus cavernosum by use of surface electroporation (Q35164806) (← links)
• Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse (Q35188822) (← links)
• Hypogonadism and erectile dysfunction: the role for testosterone therapy (Q35204827) (← links)
• What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. (Q35606352) (← links)
• A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. (Q35628328) (← links)
• The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience (Q36116915) (← links)
• Differential expression of nerve injury-induced protein 1 (ninjurin 1) in in vivo and in vitro models for diabetic erectile dysfunction (Q36284761) (← links)
• Gene and stem cell therapy for erectile dysfunction (Q36359862) (← links)
• Optimizing postoperative sexual function after radical prostatectomy (Q36379338) (← links)
• Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction (Q36395193) (← links)
• Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence (Q37018954) (← links)
• Association Between Dosage Frequency and the Treatment Outcomes of Sildenafil in Young and Middle-aged Men With Erectile Dysfunction: A Chinese, Multicenter, Observational Study (Q40769021) (← links)
• Effect of sildenafil on nocturnal erections of potent men. (Q44467340) (← links)
• A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction (Q44704627) (← links)
• A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction (Q44764447) (← links)
• Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study (Q44944221) (← links)
• Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients (Q45128190) (← links)
• Clinical application of prognostic factors for patients with organic causes of erectile dysfunction on 100 mg of sildenafil citrate (Q45233165) (← links)
• Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction (Q45243766) (← links)
• Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers (Q45262856) (← links)
• cAMP-dependent post-translational modification of neuronal nitric oxide synthase neuroprotects penile erection in rats (Q46324991) (← links)
• Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients (Q46738583) (← links)
• Dickkopf2 rescues erectile function by enhancing penile neurovascular regeneration in a mouse model of cavernous nerve injury (Q47155631) (← links)
• PDGF-mediated PI3K/AKT/β-catenin signaling regulates gap junctions in corpus cavernosum smooth muscle cells (Q47365660) (← links)
• Penile neurovascular structure revisited: immunohistochemical studies with three-dimensional reconstruction. (Q47819112) (← links)
• Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats (Q48005881) (← links)
• Can written information material help to increase treatment motivation in patients with erectile dysfunction? A survey of 1188 men. (Q48413515) (← links)
• Longitudinal changes in erectile function after thulium:YAG prostatectomy for the treatment of benign prostatic obstruction: a 1-year follow-up study (Q48623266) (← links)
• Should assessment of penetrative sexual activity be used as the treatment arbiter in the management of Peyronie's disease? (Q51587217) (← links)
• Intracavernous delivery of clonal mesenchymal stem cells rescues erectile function in the streptozotocin-induced diabetic mouse. (Q52892269) (← links)
• Combination of stromal vascular fraction and gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction (Q64377072) (← links)
• Response to on-demand vardenafil was improved by its daily usage in hypertensive men (Q84868634) (← links)
• Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse (Q92287415) (← links)
• Combined treatment with extracorporeal shockwaves therapy and an herbal formulation for activation of penile progenitor cells and antioxidant activity in diabetic erectile dysfunction (Q95261288) (← links)